Physician profile
Leah Cohen
NPI 1215664305
$1,224.77
in general payments reported to CMS, 2019-2025
14 companies · $745 in 2025
The $745 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $479 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196.74 | 2024-2025 | Linzess, Creon, Ubrelvy |
| Esperion Therapeutics, INC. | $184.07 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $176.50 | 2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $137.74 | 2024 | Xarelto |
| Novo Nordisk INC | $133.05 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $105.88 | 2025 | |
| Radius Health, INC. | $98.85 | 2024-2025 | Tymlos |
| Amgen INC. | $34.35 | 2024 | Tepezza, Repatha |
| Regeneron Healthcare Solutions, INC. | $33.44 | 2024 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.14 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $25.82 | 2024 | Ajovy |
| Astrazeneca Pharmaceuticals Lp | $22.59 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $22.42 | 2024 | Trintellix |
| Sumitomo Pharma America, INC. | $21.18 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.